ArticleAnnals of surgical oncology2025
Survival Impact of Adjuvant Nivolumab Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemotherapy with Docetaxel Plus 5-Fluorouracil and Cisplatin.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer.Annals of surgical oncology · 2026Article
- Neoadjuvant Chemoimmunotherapy Versus Standard Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2026Article
- Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study.Annals of surgical oncology · 2026Article
- Article
- Heterogeneity of adjuvant therapy effectiveness across post-neoadjuvant pathologic strata in esophageal squamous cell carcinoma: a retrospective cohort study.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Learning curve for the abdominal procedure in total robot-assisted minimally invasive esophagectomy with simultaneous cervical approach: an initial experience.BMC surgery · 2026Article
- Survival Outcomes of Adjuvant Nivolumab after Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
- Lymph node ratio predicts adjuvant chemotherapy benefit in esophageal squamous cell carcinoma.The oncologist · 2025Article
- Immunotherapy for high-grade endometrial stromal sarcoma: a narrative review bridging molecular insights to clinical translation.Frontiers in immunology · 2025Review
- Early Initiation of Adjuvant Nivolumab After Esophagectomy Is Associated With Immune-related Liver Injury.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of adjuvant nivolumab following neoadjuvant chemotherapy in managing locally advanced esophageal cancer remains unclear. This study evaluated the survival benefits of adjuvant nivolumab after neoadjuvant chemotherapy with a docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
methodsThis single-center, retrospective study included 439 consecutive patients with locally advanced ESCC who underwent radical esophagectomy following neoadjuvant DCF chemotherapy. The approval of adjuvant nivolumab has led to patients with pathological lymph node metastasis following preoperative treatment becoming eligible for treatment.
resultsAmong the 439 patients included, 379 and 60 received neoadjuvant DCF (neoDCF group) and adjuvant nivolumab after neoadjuvant DCF (neoDCF+AdNivo group), respectively. Disease-free survival (DFS) remained comparable despite differences in pathological lymph node metastasis (53% vs. 100%). After propensity score matching, adjuvant nivolumab yielded a significant improvement in DFS and overall survival (OS) (2-year DFS: 60.2% vs. 44.9%, hazard ratio [HR] 0.49, 95% confidence interval [CI] 0.28-0.83, p = 0.009; 2-year OS: 94.1% vs. 64.0%, HR 0.17, 95% CI 0.06-0.50, p = 0.001). The 1-year postoperative recurrence rate in the neoDCF+AdNivo group was lower (23% vs. 47%, p = 0.007). Subgroup analysis revealed a marked improvement in DFS in patients with ypT3 or ypN2 disease, particularly in those with ypStage III disease. Adjuvant nivolumab and ypN stage were identified as independent prognostic factors for DFS.
conclusionAdjuvant nivolumab therapy following neoadjuvant DCF chemotherapy may improve survival outcomes in patients with locally advanced ESCC, with particularly strong benefits being observed in ypStage III.
Indexed as
Identifiers
40310483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.